[go: up one dir, main page]

NO20076588L - Sammensetninger som omfatter blodplateagregeringsinhibitor i nanopartikkelform og med kontrollert frigjoring - Google Patents

Sammensetninger som omfatter blodplateagregeringsinhibitor i nanopartikkelform og med kontrollert frigjoring

Info

Publication number
NO20076588L
NO20076588L NO20076588A NO20076588A NO20076588L NO 20076588 L NO20076588 L NO 20076588L NO 20076588 A NO20076588 A NO 20076588A NO 20076588 A NO20076588 A NO 20076588A NO 20076588 L NO20076588 L NO 20076588L
Authority
NO
Norway
Prior art keywords
platelet aggregation
aggregation inhibitor
nano
compositions
particle
Prior art date
Application number
NO20076588A
Other languages
English (en)
Inventor
Gurvinder Singh Rekhi
Gary Liversidge
Scott Jenkins
John Devane
Niall Fanning
Paul Stark
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Publication of NO20076588L publication Critical patent/NO20076588L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Den foreliggende oppfinnelsen tilveiebringer en sammensetning som omfatter en blodplateaggregeringshemmer, for eksempel cilostazol eller et salt eller derivat av dette, som kan brukes ved behandlingen eller ved forebygging av iskemiske symptomer. Oppfinnelsen tilveiebringer en sammensetning som omfatter nanopartikler som omfatter blodplateaggregeringshemmeren og minst én overflatestabilisator. Nanopartiklene har en effektiv midlere partikkelstørrelse på mindre enn omtrent 2000 nm. Oppfinnelsen tilveiebringer også en sammensetning som leverer en blodplateaggregeringshemmer eller nanopartikler som inneholder denne, på en pulserende eller kontinuerlig måte.
NO20076588A 2005-05-23 2007-12-20 Sammensetninger som omfatter blodplateagregeringsinhibitor i nanopartikkelform og med kontrollert frigjoring NO20076588L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68362005P 2005-05-23 2005-05-23
PCT/US2006/019905 WO2008030209A2 (en) 2005-05-23 2006-05-23 Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor

Publications (1)

Publication Number Publication Date
NO20076588L true NO20076588L (no) 2008-02-20

Family

ID=39153748

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076588A NO20076588L (no) 2005-05-23 2007-12-20 Sammensetninger som omfatter blodplateagregeringsinhibitor i nanopartikkelform og med kontrollert frigjoring

Country Status (12)

Country Link
US (1) US20090297596A1 (no)
EP (1) EP1937218A2 (no)
JP (1) JP2008545808A (no)
KR (1) KR20080047509A (no)
CN (1) CN101287451A (no)
BR (1) BRPI0609982A2 (no)
CA (1) CA2611506A1 (no)
EA (1) EA200702595A1 (no)
IL (1) IL187567A0 (no)
NO (1) NO20076588L (no)
WO (1) WO2008030209A2 (no)
ZA (1) ZA200710000B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9775819B2 (en) 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
US8779146B2 (en) 2010-04-28 2014-07-15 Nuformix Limited Cilostazol cocrystals and compositions
WO2011146583A2 (en) 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet formulations
KR101282847B1 (ko) * 2011-07-27 2013-07-05 조선대학교산학협력단 실로스타졸을 함유하는 고체분산체 및 이를 포함하는 약학 조성물
BR112014031154A2 (pt) * 2012-06-15 2017-08-08 Foundation For Biomedical Res And Innovation agente profilático e/ou terapêutico para deficiência cognitiva leve; e agente de melhoria do fluxo intersticial
TWI697337B (zh) * 2013-08-07 2020-07-01 學校法人近畿大學 奈米粒子或奈米粒子組成物之製造方法，及支架或球囊導管之製造方法
CN103980326A (zh) * 2014-05-05 2014-08-13 珀莱雅化妆品股份有限公司 一种超临界co2反胶束萃取红景天苷的制备方法
KR101869406B1 (ko) * 2015-11-25 2018-07-24 한국유나이티드제약 주식회사 방출제어형 경질캡슐 제제
CN112592379B (zh) * 2020-12-18 2021-11-16 广东药科大学 一种β-D-葡萄糖短链脂肪酸酯化合物及其制备方法和应用
CN114796217B (zh) * 2021-01-29 2025-01-24 南京宁丹新药技术有限公司 一种含有西洛他唑的组合物在制备治疗脑血管病药物中的应用
CN117982677B (zh) * 2024-02-05 2025-09-09 沈阳药科大学 背载血小板激活抑制剂纳米粒的工程化血小板及其制备方法及应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DK0644755T3 (da) * 1992-06-10 1997-09-22 Nanosystems Llc Overflademodificerede NSAID-nanopartikler
US6117455A (en) * 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
RU2236847C2 (ru) * 1998-11-02 2004-09-27 Илан Корпорейшн, Плк. Композиции в виде множества частиц с модифицированным высвобождением
JP4748839B2 (ja) * 1999-03-25 2011-08-17 大塚製薬株式会社 シロスタゾール製剤
EG23951A (en) * 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
US7138143B1 (en) * 1999-09-30 2006-11-21 Otsuka Pharmaceutical Company, Limited Coated preparation soluble in the lower digestive tract
WO2001064164A2 (en) * 2000-02-28 2001-09-07 Genesegues, Inc. Nanocapsule encapsulation system and method
EP1341521B1 (en) * 2000-11-20 2009-01-07 Elan Pharma International Limited Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6573382B2 (en) * 2001-06-29 2003-06-03 Grayson Walker Stowell Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
CA2456806C (en) * 2001-08-08 2011-10-18 Brown University Research Foundation Methods for micronization of hydrophobic drugs
TW200301135A (en) * 2001-12-27 2003-07-01 Otsuka Maryland Res Inst Inc Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
CA2534924A1 (en) * 2003-08-08 2005-02-24 Elan Pharma International Ltd. Novel metaxalone compositions
US20050255155A1 (en) * 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Modified release cilostazol compositions
CN101212954A (zh) * 2005-05-10 2008-07-02 伊兰制药国际有限公司 纳米粒氯吡格雷制剂
EA200800041A1 (ru) * 2005-06-13 2008-04-28 Элан Фарма Интернэшнл Лтд. Составы с наночастицами клопидогреля, содержащие комбинацию клопидогреля и аспирина

Also Published As

Publication number Publication date
WO2008030209A2 (en) 2008-03-13
WO2008030209A3 (en) 2008-07-03
EA200702595A1 (ru) 2008-12-30
JP2008545808A (ja) 2008-12-18
KR20080047509A (ko) 2008-05-29
CN101287451A (zh) 2008-10-15
EP1937218A2 (en) 2008-07-02
IL187567A0 (en) 2011-08-01
BRPI0609982A2 (pt) 2010-05-18
CA2611506A1 (en) 2006-11-23
US20090297596A1 (en) 2009-12-03
ZA200710000B (en) 2009-12-30

Similar Documents

Publication Publication Date Title
NO20076588L (no) Sammensetninger som omfatter blodplateagregeringsinhibitor i nanopartikkelform og med kontrollert frigjoring
NO20076692L (no) Nanopartikulaere acetaminofenformuleringer
NO20073289L (no) Nanopartikkelsammensetninger med kontrollert frigjoring som omfatter cephalosporin
NO20073559L (no) Nanopartiklulaere tacrolimus-formuleringer
NO20076215L (no) Nanopartikulaere clopidogrelformuleringer
MX2010009866A (es) Composiciones de inhibidores de angiogenesis en nanoparticulas.
NO20075294L (no) Nanopartikulaere bifosfatforbindelser
NO20080202L (no) Nanopartikulaere clopidogrel og aspirin kombinasjonsformuleringer
HK1254398A1 (zh) 納米粒子組合物的生物標誌物
AR063940A1 (es) Formulaciones de posaconazol nanoparticulado
NO20092639L (no) 4-fenyl-6-(2,2,2-trifluor-1-fenyletoksy)pynmidinbaserte forbindelser og anvendelser derav
NO20073334L (no) Nanopartikulaert benzotiofenformuleringer
WO2009115267A3 (de) Diaminopyrimidine als pflanzenschutzmittel
EA200701442A1 (ru) Композиции наночастиц кандесартана
WO2010048149A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
PE20071184A1 (es) Compuestos de aminoisoindolina para el tratamiento del lupus cutaneo
ATE385777T1 (de) Nanopartikelzusammensetzungen von mitogen- aktivierten protein (map) kinase inhibitoren
WO2007015866A3 (en) Inhibitors of p38 kinase and methods of treating inflammatory disorders
PH12015500678A1 (en) Crystalline forms of a factor xia inhibitor
SA520412434B1 (ar) تركيبات، مجموعات، طرق واستخدامات للتنظيف، التطهير، التعقيم و/أو العلاج
WO2012001093A3 (en) Liquid formulations of rupatadine fumarate
WO2010084398A3 (en) Mouth rinse compositions including chemically modified silica or silicate materials for sustained delivery to tooth surfaces
WO2006105167A3 (en) Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
WO2009114325A3 (en) Methotrexate adjuvants to reduce toxicity and methods for using the same
WO2007067519A3 (en) The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application